Results 211 to 220 of about 9,169,598 (279)

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait, Anna Cargnoni, Franco Scaldaferri, Loris Lopetuso, Antonietta Rosa Silini, Ornella Parolini   +5 more
wiley   +1 more source

Prognostic performance of preoperative systemic inflammatory biomarkers in upper tract urothelial carcinoma after radical nephroureterectomy: a systematic review and meta-analysis of NLR, MLR, PLR, SII and SIRI. [PDF]

Front Oncol
Wang G, Dong X, Zhang X, Gu C, Hu T, Yang F, Wang D, Mao Y, Ren S.   +8 more
europepmc   +1 more source

DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy

MedComm, Volume 7, Issue 9, September 2026.
This review synthesizes the expanding biology of PAMPs and DAMPs, from their molecular sources and sensing mechanisms to regulatory networks that govern inflammation and homeostasis. Spanning from classical immune activation to trained immunity and interorgan communication, we highlight the interplay between PAMPs and DAMPs and their context‐dependent ...
Xuanxuan Yu, Yuqin Jin, Baochao Li, Jie Deng, Yiwen Zhou, Jinglun Zhang, Huang Li   +6 more
wiley   +1 more source

Tumor-Infiltrating Lymphocytes and Tumor Budding: Emerging Prognostic Markers in Breast Cancer. [PDF]

Cureus
Rastogi N, Ghosh S, Sameer P, Mishra D, Guha P.   +4 more
europepmc   +1 more source

Clinical Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy for Triple‐Negative Breast Cancer and Tumor Immune Microenvironment Analysis: A Prospective‐Retrospective Cohort Study

MedComm, Volume 7, Issue 9, September 2026.
Cohort Study Design:Between January 2019 and July 2023, 276 stage II‐III TNBC patients were enrolled in this study, including 56 in the NIC cohort and 220 in the NAC cohort. Due to 17 cases of ineligible criteria, 5 with withdrawal of informed consent, 198 patients in the NAC cohort completed NAC and underwent surgical resection.
Yongsheng Wang, Pengfei Qiu, Yuechen Wang, Xingchen Meng, Jiaxin Zhang, Haiqiang Liu, Zhiqiang Shi, Zhaopeng Zhang, Xiao Sun, Chunjian Wang, Xiangjing Meng, Chunhui Zheng   +11 more
wiley   +1 more source

Prognostic value of pretreatment systemic immune-inflammation index for overall survival in esophageal squamous cell carcinoma in China: a systematic review and meta-analysis. [PDF]

J Thorac Dis
He C, Chen K, Zhao Y, Ni L, He R, Zhang Y, Sun N, Li G, Lai Z.   +8 more
europepmc   +1 more source

Long‐Term Prognosis and Immunotranscriptomic Landscape in Esophageal Squamous Cell Carcinoma With Different Pathological Responses to Neoadjuvant Chemoradiotherapy: A Retrospective Cohort Study

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This study comprehensively characterizes the long‐term prognosis and immunotranscriptomic landscape associated with different tumor regression grades (TRGs) in esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemoradiotherapy. By integrating bulk RNA‐seq, single‐cell transcriptomics, and multiplexed immunohistochemistry, we demonstrate ...
Jianye Yuan, Zelin Weng, Xinke Zhang, Fangqi Deng, Zihui Tan, Jian Zhong, Rui Chen, Xiuying Xie, Xiaodan Lin, Ting Lin, Yan Huang, Qianwen Liu, Jing Wen, Jianhua Fu   +13 more
wiley   +1 more source

Surgical Management of Parapharyngeal Metastases from Thyroid Carcinoma: A Systematic Review and Patient-Level Analysis of the Role of Lateral Neck Dissection. [PDF]

Cancers (Basel)
Chiari F, Reppucci M, Fermi M, Di Dalmazi G, Palatino V, Filippini DM, Motta G, Mercante G, Presutti L, Caporale CD, Guarino P.   +10 more
europepmc   +1 more source

TRMT61A‐Mediated m1A Modification Suppresses FDX1 Translation to Drive Cuproptosis Evasion and Radioresistance in Hepatocellular Carcinoma

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This study identifies tRNA methyltransferase 61 A (TRMT61A)‐mediated N1‐methyladenosine (m1A) modification as a driver of radioresistance in hepatocellular carcinoma (HCC) by suppressing cuproptosis. TRMT61A methylates FDX1 mRNA, enabling YTHDF3 recognition and eRF1 recruitment to inhibit FDX1 translation.
Yunyun Xiao, Yue Li, Zelei Li, Rui Wang, Dongni Shi, Yanling Wen, Yibing Pan, Chen Lin, Junguo Bu, Libing Song, Hui Dai   +10 more
wiley   +1 more source